1. Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin,SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate. 2012; 72(3):291-300.(SCI)

2. Hsiu-Li Yang, Li-Jiuan Shen, Chih-Fen Hunag, Chia-Yu Lin, Wen-Hwei Chen, Ya-Ting Hsieh, Fe-Lin Lin Wu*. Are brand-name drugs of better quality than generics? research at a medical center in Taiwan. Journal of Food and Drug Analysis 2012; 20:1-6.(SCI)

3. Chia-Yu Lin, Li-Jiuan Shen, Chih-Fen Huang, Hsiu-Li Yang, Ying-Yung Chen, Fe-Lin Lin Wu*. Beyond-Use Date of the Extemporaneous Morphine Hydrochloride Oral Solution. Journal of Food and Drug Analysis (2012,Accepted)

4. Li-Jiuan Shen, Hua Chou, Chih-Fen Huang, Guann-Miaw Chou, Wing Kai Chan, Fe-Lin Lin Wu*. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan. Contemporary Clinical Trials 2011; 32:485–491.(SCI)

5. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010; 70(11):4580-9.(SCI)

6. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010; 29(22):3196-207.